LA JOLLA, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- MyDx, Inc. (OTCQB:MYDX), a rapidly growing science and technology company that has developed
MyDx®, a multi-use handheld chemical analyzer and application, today announced that fueled by last week’s historic
passage of state ballot initiatives in eight new states passing cannabis laws, the Company’s “MyDx One” smart-phone app for its
Analyzer has catapulted to the top of the iOS App Store charts. As a direct result, the Company has already experienced an
immediate increase in revenues.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ab90cdd0-daec-4d16-9b1f-362921526b4d
MyDx One App Tops the Apple iOS Charts
MyDx One is a free app, downloadable with or without owning a multi-use MyDx Analyzer. Even without owning the Analyzer, MyDx One
provides users free valuable information to help them find and track cannabis strains and their effectiveness in treating various
ailments or producing desired experiences.
As of yesterday, MyDx One was listed as the number one-ranked free app in iOS App Store under the Medical Category (Note: iPhone
users, please click on App Store, Top Charts, select Medical Category, Free to view rankings).
As of yesterday, MyDx One was the top trending app in the App Store Search for the keyword “cannabis”.
As of Saturday November 12, 2016, of all the free apps in the iOS App Store, MyDx One was ranked #54, ahead of Google Drive at
#55 and just behind Pokémon GO at #53.
“Our ability to achieve the number one ranking in the Apple Store’s medical category is a clear reflection of the industry’s
increasing acceptance of our platform and its unique ability to help consumers identify a strain that meets their needs,” said
Daniel Yazbeck, Chairman and Chief Executive Officer of MyDx. As a result, we are continuing to grow one of the industry’s
largest crowdsourced databases with invaluable information that could have only been gathered through the grass roots effort
implemented by the CannaDx team since its launch close to one year ago.”
About MyDx, Inc.
MyDx, Inc. (OTCQB:MYDX) is a chemical detection and sensor technology company based in San Diego, California whose mission is to
help people Trust & Verify® what they put into their minds and bodies. The Company developed MyDx®, a
patented, affordable portable analyzer that provides real-time chemical analysis and fits in the palm of the user’s hand. The
multi-use MyDx analyzer leverages over a decade of established chemical detection technology to measure chemicals of interest. The
Company owns a substantial and growing intellectual property portfolio of patents covering its technology. The MyDx
CannaDxTM, AquaDxTM and OrganaDxTM sensors are now commercialized, and the
AeroDxTM application is next in line. All Sensors will be compatible with a MyDx App that empowers consumers to
test the chemical composition of what they eat, drink and inhale. For more information, please visit www.cdxlife.com.
Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933,
as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking
statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating
to future operations and results. Any statements in this press release that are not statements of historical fact may be considered
to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal,"
"objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking
statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not
limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new
products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the
marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing,
technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed
with the Securities and Exchange Commission, available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov.
The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.
Investor Contact: Phillip Sugarman, Vice President Investor Relations Partners Phone: 818-280-6800 psugarman@irpartnersinc.com
